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ABSTRACT	  
Peri-­‐implant	   diseases	   are	   defined	   as	   inflammatory	   lesions	   of	   the	   surrounding	   peri-­‐implant	  
tissues,	   and	   they	   include	   peri-­‐implant	   mucositis	   (inflammatory	   lesion	   limited	   to	   the	  
surrounding	  mucosa	  of	  an	  implant)	  and	  peri-­‐implantitis	  (inflammatory	  lesion	  of	  the	  mucosa,	  
affecting	   the	   supporting	  bone	  with	   resulting	   loss	  of	  osseointegration).	   This	   review	  aims	   to	  
describe	   the	   different	   approaches	   to	   manage	   both	   entities	   and	   to	   critically	   evaluate	   the	  
available	  evidence	  on	  their	  efficacy.	  	  
Therapy	  of	  peri-­‐implant	  mucositis	  and	  non-­‐surgical	  therapy	  of	  peri-­‐implantitis	  usually	  involve	  
the	  mechanical	  debridement	  of	  the	  implant	  surface	  by	  means	  of	  curettes,	  ultrasonic	  devices,	  
air-­‐abrasive	   devices	   or	   lasers,	   with	   or	   without	   the	   adjunctive	   use	   of	   local	   antibiotics	   or	  
antiseptics.	  The	  efficacy	  of	  these	  therapies	  has	  been	  demonstrated	  for	  mucositis.	  	  Controlled	  
clinical	  trials	  show	  an	  improvement	  in	  clinical	  parameters,	  especially	  in	  bleeding	  on	  probing.	  
For	   peri-­‐implantitis,	   the	   results	   are	   limited,	   especially	   in	   terms	   of	   probing	   pocket	   depth	  
reduction.	  
Surgical	  therapy	  of	  peri-­‐implantitis	  is	  indicated	  when	  non-­‐surgical	  therapy	  fails	  to	  control	  the	  
inflammatory	   changes.	   The	   selection	   of	   the	   surgical	   technique	   should	   be	   based	   on	   the	  
characteristics	  of	  the	  peri-­‐implant	  lesion.	  In	  presence	  of	  deep	  circumferential	  and	  intrabony	  
defects	   surgical	   interventions	   should	  be	  aimed	   for	   thorough	  debridement,	   implant	   surface	  
decontamination	  and	  defect	  reconstruction.	  In	  presence	  of	  defects	  without	  clear	  bony	  walls	  
or	  with	  a	  predominant	  suprabony	  component,	  the	  aim	  of	  the	  surgical	  intervention	  should	  be	  
the	   thorough	  debridement	  and	   the	   repositioning	  of	   the	  marginal	  mucosa	   that	  enables	   the	  
patient	  for	  effective	  oral	  hygiene	  practices,	  although	  this	  aim	  may	  compromise	  the	  aesthetic	  
result	  of	  the	  implant	  supported	  restoration.	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Introduction	  
The	   use	   of	   dental	   implants	   for	   supporting	   prosthetic	   rehabilitations	   has	   shown	   highly	  
satisfactory	  results	  for	  the	  restoration	  of	  the	  patient’s	  function	  and	  aesthetics,	  as	  well	  as	  in	  
terms	  of	  long-­‐term	  survival	  (2).	  Dental	  implants,	  however,	  can	  lose	  supportive	  bone,	  even	  in	  
cases	  of	  successful	  osseointegration.	  The	  main	  cause	  for	  this	  loss	  of	  crestal	  bone	  surrounding	  
an	  implant	  is	   local	   inflammation	  during	  the	  course	  of	  peri-­‐implant	  diseases.	  These	  diseases	  
are	  defined	  as	  inflammatory	  lesions	  of	  the	  surrounding	  peri-­‐implant	  tissues	  and	  include	  two	  
different	   entities:	   peri-­‐implant	  mucositis	   and	   peri-­‐implantitis	   (7).	   Peri-­‐implant	  mucositis	   is	  
defined	  as	  an	   inflammatory	   lesion	   limited	   to	   the	  surrounding	  mucosa	  of	  an	   implant,	  while	  
peri-­‐implantitis	  is	  an	  inflammatory	  lesion	  of	  the	  mucosa,	  which	  affects	  the	  supporting	  bone	  
with	  loss	  of	  osseointegration	  (19).	  	  
	  
Both	   peri-­‐implant	   diseases	   are	   infectious	   in	   nature	   and	   caused	   by	   bacteria	   from	   dental	  
biofilms	  (18).	  A	  recent	  review	  concluded	  that	  microbiota	  associated	  to	  peri-­‐implant	  diseases	  
is	   a	   mixed	   anaerobic	   infection,	   with	   a	   similar	   composition	   to	   that	   of	   the	   subgingival	  
microbiota	  of	   chronic	  periodontitis;	  although	  some	  cases	  may	  be	  specifically	  associated	   to	  
other	   bacterial	   species,	   such	   as	   Peptostreptococcus	   spp.	   or	   Staphylococcus	   spp.	   (22).	  
Although	  bacterial	  pathogens	  represent	  the	   initial	  step	  of	  the	  disease	  process,	   the	  ensuing	  
local	  inflammatory	  response	  and	  the	  misbalance	  in	  the	  host-­‐parasite	  interaction	  seems	  key	  
in	  the	  pathogenesis	  of	  the	  tissue	  destruction	  defining	  these	  diseases.	  Different	  risk	  indicators	  
have	  been	  identified,	  which	  may	  intervene	  in	  the	  pathogenesis	  favouring	  tissue	  destruction,	  
such	  as:	  poor	  oral	  hygiene,	  a	  history	  of	  periodontitis	  and	  cigarette	  smoking.	  Less	  evidence	  
has	  been	  demonstrated	  for	  the	  role	  of	  diabetes	  and	  alcohol	  consumption	  (13).	  The	  possible	  
role	   of	   other	   factors,	   such	   as	   genetic	   traits,	   the	   implant	   surface	  or	   the	   lack	   of	   keratinised	  
mucosa,	  are	  also	  under	  validation	  (63).	  
	  
Different	   methods	   have	   been	   used	   to	   assess	   peri-­‐implant	   tissue	   health	   and	   to	   diagnose	  
these	  disease	  entities.	  They	  include	  peri-­‐implant	  probing,	  analyses	  of	  peri-­‐implant	  crevicular	  
fluid	  or	  saliva,	  evaluation	  of	  the	  peri-­‐implant	  microbiota	  and	  radiographic	  evaluation	  of	  the	  
peri-­‐implant	  bone	  levels.	  The	  consensus	  today	  indicates	  that	  changes	  in	  probing	  depth	  (PPD),	  
presence	   of	   bleeding	   on	   probing	   (BOP)	   and	   suppuration	  must	   be	   evaluated	   to	   assess	   the	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peri-­‐implant	  tissues,	  while	  radiographs	  should	  be	  used	  to	  confirm	  peri-­‐implant	  bone	  loss	  (13,	  
57).	  	  
	  
Peri-­‐implant	   diseases	   are	   important	   disease	   entities	   due	   to	   their	   high	   prevalence	   and	   the	  
lack	  of	  a	   standard	  mode	  of	   therapy	   (7,	  35).	  Although	   the	  current	  epidemiological	  data	  are	  
limited,	  peri-­‐implant	  mucositis	  has	  been	  reported	  to	  affect	  80%	  of	  the	  subjects	  using	  dental	  
implants	   and	   50%	   of	   the	   implants,	   while	   peri-­‐implantitis	   affects	   between	   28-­‐56%	   of	   the	  
subjects	  and	  between	  12-­‐43%	  of	  the	  implants.	  
	  
This	  reviews	  aims	  to	  describe	  the	  different	  approaches	  to	  treat	  peri-­‐implant	  diseases	  and	  to	  
critically	  evaluate	  the	  available	  evidence	  to	  support	  the	  different	  proposed	  therapies.	  With	  
this	  purpose	  we	  shall	  use	  a	   recently	  published	  systematic	   review	   from	  our	   research	  group	  
where	  only	  controlled	  studies	  were	  considered	  (11).	  In	  addition,	  relevant	  recently	  published	  
studies	  were	  included.	  
	  
	  
Case	  definitions	  for	  peri-­‐implant	  diseases	  
Table	   1	   depicts	   the	   different	   diagnostic	   criteria	   used	   to	   define	   peri-­‐implant	   mucositis.	  
Although	   the	   definitions	   are	   heterogeneous,	   all	   the	   selected	   studies,	   but	   one	   (28)	   have	  
included	  BOP	  of	  the	  peri-­‐implant	  mucosa.	  
	  
Peri-­‐implant	  disease	  definition	  also	  varied	  across	  studies	  (see	  Table	  2),	  but	  normally	  included	  
presence	   of	   BOP,	   deep	   PPD	   (Figure	   1)	   and	   bone	   loss,	   although	   using	   different	   threshold	  
values	  (Figure	  2).	  These	  values	  for	  PPD	  were	  always	  deeper	  than	  3	  mm	  and	  ranged	  from	  1.8	  
to	  3	  mm	  for	  bone	  loss.	  Only	  one	  study	  had	  exclusively	  a	  bone	  loss	  criterion	  (>50%)	  (5).	  
	  
	  
Treatment	  approaches	  for	  peri-­‐implant	  diseases	  
The	  evaluation	  of	  the	  different	  therapies	  is	  based	  on	  a	  recently	  published	  systemic	  review	  of	  
controlled	   studies	   with	   the	   addition	   of	   recently	   published	   trials	   (11).	   The	   evaluation	   has	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been	  divided	  in	  three	  parts:	  therapy	  of	  peri-­‐implant	  mucositis,	  non-­‐surgical	  therapy	  of	  peri-­‐
implantitis	  and	  surgical	  therapy	  of	  peri-­‐implantitis.	  
	  
	  
Peri-­‐implant	  mucositis	  therapy	  
The	  treatment	  of	  peri-­‐implant	  mucositis	  usually	  includes	  mechanical	  debridement	  of	  biofilm	  
and	  calculus.	  This	  therapy	  may	  be	  rendered	  either	  through	  a	  professional	  intervention	  or	  by	  
the	   patient	   through	   the	   home-­‐use	   oral-­‐hygiene	   techniques.	   In	   addition,	   adjunctive	  
antimicrobials,	  such	  as	  antiseptics,	  local	  or	  systemic	  antibiotics,	  may	  be	  used	  in	  conjunction	  
with	  mechanical	  debridement	  alone	  or	  with	  mechanical	  debridement	  and	  mechanical	  plaque	  
control	  protocols.	  With	  all	  these	  interventions,	  it	  is	  necessary	  to	  highlight	  the	  importance	  on	  
the	   role	   of	   the	   subject’s	   own	   infection	   control	   through	   the	   proper	   motivation	   and	   oral	  
hygiene	  practices	   in	  order	   to	  prevent	   the	   reformation	  of	  peri-­‐implant	  biofilm	  and	  calculus	  
around	  the	  implant.	  
	  
Peri-­‐implant	  mucositis	  therapy:	  professional	  interventions	  
	  
Mechanical	   debridement	   alone	   involves	   the	   supra-­‐	   and	   subgingival	   debridement	   of	   the	  
implant	  surface,	  the	  implant	  neck	  and	  the	  abutment.	  The	  main	  objective	  is	  to	  remove	  peri-­‐
implant	   biofilm	   and	   calculus	   without	   altering	   the	   implant	   surface	   with	   the	   goal	   of	  
reestablishing	  a	  healthy	  peri-­‐implant	  mucosa	  (12,	  14).	  	  	  
	  
Different	  debridement	  systems	  have	  been	  evaluated,	  normally	  in	  combination	  with	  polishing	  
the	   implant	   surface	   and/or	   the	   prosthetic	   components	  with	   a	   rubber	   cup	   and	   a	   polishing	  
paste	  or	  with	  an	  abrasive	  sodium-­‐carbonate	  air-­‐powder	  system.	  
	  
a)	  Curettes	  of	  different	  materials	  to	  be	  used	  specifically	  to	  debride	  implant	  surfaces:	  	  
• Steel	   curettes	  have	  an	  external	  hardness	  higher	   than	   titanium,	   thus,	   they	  are	  not	  
indicated	   for	   cleaning	   titanium	   implants.	  Nevertheless,	   they	   can	  be	  used	   in	   other	  
implant	  surfaces,	  such	  as	  titanium	  zirconoxide	  or	  titanium	  oxinitride	  (45).	  
• Titanium-­‐coated	  curettes	  have	  a	  similar	  hardness	  to	  the	  titanium	  surface	  and	  thus	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do	  not	  scratch	  its	  surface	  (12)	  (Figure	  3).	  	  
• Carbon	   fiber-­‐curettes	   are	   softer	   than	   the	   implant	   surface	   and	   therefore	   remove	  
bacterial	   deposits	   without	   damaging	   the	   surface,	   although	   they	   easily	   break	   (14)	  
(Figures	  3	  and	  4).	  	  
• Teflon	  curettes	  have	  similar	  properties	  to	  carbon	  fiber	  curettes	  and	  they	  have	  been	  
proposed	  for	  its	  use	  in	  combination	  with	  air-­‐abrasive	  systems	  (21)	  (Figure	  6).	  	  
• Plastic	   curettes	   are	   even	   more	   fragile	   and	   have	   limited	   debriding	   capacity	   (28)	  
(Figure	  5).	  	  
	  
b) Ultrasonic	  devices	  with	  polyether-­‐etherketone-­‐coated	  tips	   (Figure	  7).	  This	   is	  a	  modified	  
tip,	  made	  of	   a	  high-­‐tech	  plastic	  material,	  with	   a	   stain-­‐steel	   core.	   It	   easily	   debrides	   the	  
implant	  surface	  and	   it	   is	  comfortable	  for	  the	  patient.	  The	  purpose	   is	   to	  debride	  plaque	  
and	  calculus	  from	  all	  around	  the	  implant	  neck	  and	  the	  abutment,	   leaving	  a	  clean	  and	  a	  
smooth	  surface	  (62).	  
	  
Adjunctive	   use	   of	   antimicrobials,	   included	   chlorhexidine-­‐based	   (CHX)	   product,	  have	   been	  
used	   as	   adjuncts	   to	  mechanical	   debridement	   to	   prevent	   bacterial	   recolonization	   after	   the	  
mechanical	  treatment	  and	  to	  support	  the	  patient’s	  oral	  hygiene	  practices.	  
	  
Different	  CHX	  formulation	  and	  dosages	  have	  been	  evaluated:	  
• 20	   ml	   of	   0.12%	   CHX	   mouth	   rinse,	   once	   per	   day,	   for	   3	   months,	   after	   professional	  
prophylaxis	  (10).	  
• Powered	  subgingival	   irrigation	  with	  100	  ml	  of	  0.06%	  CHX,	  once	  daily,	   for	  3	  months,	  
after	  professional	  prophylaxis	  (10).	  
• Brushing	  with	  1	  cm	  of	  0.5%	  CHX	  gel	  around	  the	   implants	   (see	  Figure	  8),	   twice	  daily	  
for	  4	  weeks	  (14).	  
• Rinsing	  with	  10	  ml	  of	  0.12%	  CHX	  plus	  brushing	  with	  0.12%	  CHX	  gel,	  twice	  daily,	  for	  10	  
days	  after	  treatment	  (28).	  
• Full-­‐mouth	   disinfection	   protocol,	   after	   debridement	   with	   an	   ultrasonic	   device,	  
including:	  0.1%	  CHX	  gel	  applied	  subgingivally;	  brushing	  the	  dorsum	  of	  the	  tongue	  for	  
1	  min	  with	  a	  1%	  CHX	  gel;	  spraying	  each	  tonsil	   four	  times	  with	  0.2%	  CHX	  spray;	  and	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rinsing	  with	  0.2%	  CHX,	  twice,	  for	  1	  min.	  During	  the	  following	  14	  days,	  patients	  were	  
instructed	   to	   rinse	  once	  daily	   for	  30	  s	  with	  0.2%	  CHX	  and	  to	  spray	   the	   tonsils	  once	  
daily	  with	  0.2%	  CHX	  spray	  (62).	  
	  
Locally	  delivered	  antimicrobials	  have	  been	  used	  to	   increase	  the	  antibacterial	  effect	  of	  the	  
mechanical	   debridement	   and	   to	   prevent	   bacterial	   colonization	   of	   the	   implant	   surface.	  
Locally	   delivered	   tetracycline	   was	   applied	   in	   monolithic	   ethylene	   vinyl	   acetate	   fibers	  
containing	  25%	  w/v	  tetracycline	  hydrochloride.	  The	  following	  protocol	  was	  performed:	  fibers	  
were	   placed	   around	   implants	   in	   several	   circular	   layers	   until	   the	   peri-­‐implant	   space	   was	  
completely	   filled	   by	   the	   fiber;	   once	   placement	   of	   the	   delivery	   system	  was	   completed,	   an	  
isobutyl	  cyanoacrylate	  adhesive	  was	  applied	  at	  the	  mucosal	  margin	  to	  secure	  the	  fiber,	  and	  
in	  case	  of	  fiber	  loss	  prior	  to	  7	  days	  following	  the	  fiber	  placement,	  another	  fiber	  was	  placed;	  
ten	  days	  after	  initial	  placement,	  the	  fibers	  were	  removed	  (45).	  
	  
Systemic	  antimicrobials	  have	  been	  administered	  adjunctively	  to	  mechanical	  debridement	  in	  
order	   to	   achieve	   effective	   antimicrobial	   levels	   in	   the	   peri-­‐implant	   crevicular	   fluid	   and	  
therefore,	   support	   the	   antibacterial	   mechanical	   effect.	   Different	   antibiotics,	   such	   as	  
azithromycin	  at	  a	  dose	  of	  500	  mg	  per	  day,	  during	  four	  days	  have	  been	  utilized	  (12).	  
	  
Peri-­‐implant	  mucositis	  therapy:	  home-­‐use	  oral	  hygiene	  interventions	  
Mechanical	  plaque	  control	  may	  involve	  the	  use	  of	  manual	  or	  powered	  toothbrushes	  as	  well	  
as	   interproximal	   aids.	   Its	   importance	   should	   be	   highlighted;	   since	   long-­‐term	   success	   of	  
dental	   implants	  will	  depend	  on	  an	  effective	  peri-­‐implant	  supportive	   therapy	  where	  plaque	  
control	  around	  implants	  is	  key	  for	  both	  the	  primary	  prevention	  of	  peri-­‐implant	  mucositis	  and	  
its	   secondary	   prevention	   once	   treated.	   These	   recommendations	   are	   usually	   found	   in	  
protocols	  of	  primary	  and	  secondary	  prevention	  of	  peri-­‐implant	  mucositis:	  
• Manual	  squish	  grip	  brush,	  to	  be	  used	  twice	  daily	  for	  30	  seconds	  during	  a	  period	  of	  6	  
weeks	  after	  a	  professional	  removal	  of	  plaque	  from	  the	  implant	  abutments	  (60).	  
• Soft	  manual	  toothbrush	  and	  dental	  floss,	  or	  specialized	  implant	  dental	  floss	  stocked	  
by	   the	   various	   research	   sites	   and	   end-­‐tuft	   brushes	   or	   interproximal	   brushes.	   This	  
protocol	  of	  supportive	  therapy	  was	  used	  twice	  daily	  for	  a	  period	  of	  6	  years	  (65).	  	  
• Powered	   toothbrush,	   to	   be	   used	   twice	   daily	   for	   30	   seconds	   during	   a	   period	   of	   6	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weeks	  after	  a	  professional	  removal	  of	  plaque	  from	  the	  implant	  abutments.	  It	  gives	  a	  
three-­‐dimensional	   brushing	   action,	   coupling	   a	   sonic	   frequency	   and	   a	   high-­‐speed	  
oscillation	  that	  provides	  a	  deeper	  dental	  and	  peri-­‐implant	  cleaning	  (60).	  
• Counter-­‐rotational	  powered	  brush.	   It	  has	  10	  spaced	   tufts	  of	  bristles	   that	   rotate	  1.5	  
turns	  before	  reversing	   for	  another	  1.5	  turns.	  This	   reverse	  movement	   is	   intended	  to	  
increase	  the	  scrubbing	  action	  and	  to	  force	  bristles	  into	  interproximal	  and	  subgingival	  
areas.	   Adjacent	   tufts	   counter-­‐rotate	   relative	   to	   each	   other,	   which	   has	   a	   stabilizing	  
effect	  when	  the	  brush	  is	  placed	  on	  a	  given	  site.	  The	  bristle	  configuration	  is	  designed	  
to	  reach	  between	  teeth	  and	  subgingivally.	  This	  design	  is	  different	  from	  other	  leading	  
powered	  brushes,	  which	  use	  oscillating,	   vibrating	  or	  acoustic	  modes	  of	  action.	  This	  
protocol	  of	  maintenance	  was	  used	  twice	  daily	  for	  a	  period	  of	  6	  years	  (65).	  
	  
Chemical	   plaque	   control	   may	   provide	   additional	   benefits	   as	   adjuncts	   to	   tooth	   brushes	  
(manual	   or	   powered)	   and	   interdental-­‐cleaning	   devices.	   In	   the	   6th	   European	  Workshop	   in	  
Periodontology,	   it	   was	   concluded	   that	   there	   was	   a	   need	   to	   determine	   whether	  
antimicrobials	  used	  in	  periodontal	  therapy	  are	  also	  effective	  in	  the	  treatment	  of	  peri-­‐implant	  
diseases	   and	   to	   what	   extent	   initial	   improvements	   are	   sustained	   over	   long	   term	   (19).	  
Therefore,	   different	   chemical	   products	   in	   combination	   with	   mechanical	   oral	   hygiene	  
techniques	  have	  been	  studied.	  Some	  of	  these	  adjunctive	  protocols	  are	  listed:	  
• Triclosan/copolymer	  toothpaste.	  A	  0.3%	  triclosan	  and	  2.0%	  PVM/MA	  copolymer	  in	  a	  
sodium	  fluoride	  silica	  base	  toothpaste,	  in	  conjunction	  with	  a	  soft	  bristle	  brush,	  for	  6	  
months	  twice	  daily	  during	  60	  seconds	  each	  (29,	  58).	  
• Fluoride	   toothpaste.	   A	   toothpaste	   containing	   0.243	   sodium	   fluoride	   silica-­‐based	  
tooth	  paste,	  in	  conjunction	  with	  a	  soft	  bristle	  brush,	  for	  6	  months	  twice	  daily	  during	  
60	  seconds	  each	  (29,	  58).	  
• Essential	  oils	   rinse.	  After	  a	  dental	  prophylaxis,	   Listerine®	  was	  used	  after	  a	  standard	  
oral	  hygiene	  procedure,	  twice	  daily	  during	  30	  seconds	  for	  a	  period	  of	  3	  months	  (6).	  
• CHX	  rinse.	  Rinsing	  twice	  a	  day	  with	  a	  0.12%	  CHX,	   in	  conjunction	  with	  a	  soft	  manual	  
toothbrush	  and	  dental	  floss,	  specialized	  implant	  dental	  floss	  and	  end-­‐tuft	  brushes	  or	  
interproximal	  brushes.	  This	  protocol	  of	  supportive	  therapy	  was	  used	  for	  a	  period	  of	  6	  
years	  and	  CHX	  rinsing	  was	  combined	  with	   the	  use	  of	  a	  counter-­‐rotational	  powered	  
brush	  (65).	  
	   9	  
	  
Peri-­‐implant	  mucositis	  therapy:	  evaluation	  in	  controlled	  trials	  
At	   least	   seven	   randomized	   controlled	   clinical	   trials	   (RCTs)	   evaluating	   the	   therapy	   of	   peri-­‐
implant	   mucositis	   have	   been	   published	   (6,	   10,	   14,	   28,	   29,	   45,	   62).	   In	   these	   studies,	   the	  
sample	   size	   ranged	   between	   8-­‐59	   patients	   and	   the	   mean	   follow-­‐up	   varied	   from	   3	   to	   8	  
months.	  Three	  studies	  included	  patients	  with	  treated	  periodontitis	  (14,	  29,	  62);	  two	  included	  
periodontally	  healthy	  subjects	  (10,	  28);	  and	  two	  did	  not	  report	  the	  periodontal	  status	  (6,	  45).	  
	  
Studies	   can	   be	   grouped	   in	   two	   categories	   depending	   on	   whether	   the	   intervention	   was	  
professional	  or	  based	  on	  the	  patient’s	  oral	  hygiene	  practices:	  
• Professional	   mechanical	   debridement	   with	   or	   without	   the	   adjunctive	   use	   of	  
antimicrobials	  (14,	  28,	  45,	  62).	  
• Home-­‐use	   oral	   hygiene	   intervention.	   After	   an	   initial	   prophylaxis,	   patients	   were	  
instructed	   to	   use	   an	   antiseptic	   as	   adjunct	   to	   conventional	   oral	   hygiene	   techniques	  
during	  a	  certain	  period	  of	  time	  (3-­‐6months)	  (6,	  10,	  29).	  
	  
Treatment	  efficacy	   is	  based	  on	   the	  evaluation	  of	   the	  changes	   in	   the	  gingival	   inflammatory	  
parameters.	   BOP	   was	   considered	   the	   main	   clinical	   outcome	   variable,	   although	   PPD	   and	  
plaque	  index	  (Pl)	  were	  usually	  reported	  too.	  Microbiological	  outcomes	  were	  reported	  in	  two	  
articles	  (14,	  62).	  Only	  one	  study	  reported	  the	  number	  and	  percentage	  of	  cases	  of	  mucositis	  
solved	  (complete	  resolution	  of	  BOP	  at	  all	  the	  measured	  sites)	  (14).	  
	  
Based	  on	  these	  clinical	  outcomes:	  
• When	  mechanical	   debridement	   alone	   was	   compared	   to	  mechanical	   debridement	   plus	  
the	   adjunctive	   use	   of	   different	   protocols	   of	   CHX	   (14,	   28,	   62)	   or	   locally	   delivered	  
tetracycline	  (45)	  the	  reductions	  of	  BOP	  were	  significant	   in	  both	  groups,	  without	  a	  clear	  
benefit	  derived	  from	  the	  use	  of	  CHX	  or	  locally	  delivered	  tetracycline.	  The	  results	  for	  PPD	  
showed	  higher	   variability	   as	   compared	   to	  BOP.	  While	   two	   studies	   found	  a	   similar	   PPD	  
reduction	  in	  both	  groups	  (14,	  62),	  one	  found	  higher	  reductions	  in	  the	  control	  group	  (28)	  
and	   another	   did	   not	   find	   any	   change	   in	   PPD	   in	   the	   test	   or	   in	   the	   control	   groups	   (45).	  
Plaque	  index	  (PI)	  was	  not	  evaluated	  in	  one	  paper	  (14)	  and	  the	  results	  for	  the	  other	  trials	  
showed	  either	  a	  similar	  Pl	  reduction	  in	  both	  groups	  (28,	  62)	  or	  no	  changes	  in	  any	  of	  the	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groups	  (45).	  For	  microbiological	  outcomes,	  no	  differences	  could	  be	  seen	  between	  groups	  
when	  using	  PCR	  (62)	  or	  DNA	  probes	  (14).	  
• When	  evaluating	  home-­‐use	  oral	  hygiene	  interventions,	  different	  plaque	  control	  regimens	  
have	  been	  compared.	  Two	  studies	  have	  evaluated	  the	  adjunctive	  home	  use	  of	  antiseptics	  
after	   an	   initial	   prophylaxis	   (6,	   10)	   and	   one	   study	   has	   evaluated	   the	   home	   use	   of	   two	  
different	   toothpastes	  as	  unique	  treatment	  of	  peri-­‐implant	  mucositis	   (29).	  The	  reported	  
results	   are:	   a)	   a	   higher	   reduction	  of	   BOP	   and	  PI	   after	   3-­‐months	   using	   an	   essential	   oils	  
mouth	  rinse	  compared	  to	  the	  negative	  control,	  but	  no	  differences	  for	  PPD	  or	  CAL	  (6);	  b)	  a	  
greater	   reduction	   in	   PI,	   in	   the	   modified	   bleeding	   index	   and	   in	   the	   stain	   index,	   when	  
comparing	   irrigation	   with	   0.06%	   CHX	   using	   a	   powered	   oral	   irrigator	   with	   a	   special	  
subgingival	  irrigating	  tip	  to	  rinse	  with	  0.12%	  CHX	  mouth-­‐rinse	  once	  daily	  during	  3	  months	  
(10);	   c)	   a	   higher	   performance	   of	   triclosan/copolymer	   containing	   toothpaste,	   when	  
compared	  with	  a	  sodium	  fluoride	  toothpaste	  after	  a	  period	  of	  home-­‐use	  of	  6	  months	  in	  
terms	  of	  BOP,	  despite	  no	  changes	  were	  noted	  among	  groups	  for	  PI	  or	  PPD	  (29).	  
	  
Peri-­‐implant	  mucositis	  therapy:	  summary	  and	  conclusions	  
Peri-­‐implant	  mucositis	   treatment	   usually	   includes	  mechanical	   debridement	   of	   biofilm	   and	  
calculus	  either	  by	  a	  professional	   intervention	  or	  by	  home-­‐use	  oral-­‐hygiene	  techniques	  with	  
or	  without	  the	  adjunctive	  use	  of	  antimicrobials.	  	  
	  
Professional	  mechanical	   interventions	  with	  or	  without	   the	  adjunctive	  use	  of	  antimicrobials	  
have	  been	  shown	  to	  significantly	  reduce	  peri-­‐implant	  tissue	   inflammation	  (as	  evaluated	  by	  
reductions	  in	  BOP)	  and	  therefore,	  peri-­‐implant	  mucositis	  seems	  to	  be	  successfully	  treated	  by	  
professional	   mechanical	   debridement	   independently	   of	   the	   adjunctive	   use	   of	   an	  
antimicrobial.	  
	  
In	  the	  case	  of	  home-­‐use	  oral	  hygiene	  products,	  mechanical	  plaque	  control	  together	  with	  the	  
use	   of	   an	   antiseptic	  may	  benefit	   the	   treatment	   of	   peri-­‐implant	  mucositis	   in	   terms	  of	   BOP	  
reduction	  and,	  sometimes,	  in	  PI	  reduction.	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In	   summary,	   clinical	   trials	   evaluating	   the	   treatment	   of	   peri-­‐implant	   mucositis	   provide	   a	  
variety	  of	  effective	  protocols	  in	  reducing	  peri-­‐implant	  tissue	  inflammation	  and	  therefore,	  the	  
clinician	  should	  select	  those	  that	  adapt	  better	  to	  the	  specific	  patient’s	  circumstances.	  	  	  
	  
	  
Peri-­‐implantitis	  non-­‐surgical	  therapy	  
The	   basis	   for	   peri-­‐implantitis	   therapy	   is	   infection	   control	   through	   the	   debridement	   of	   the	  
implant	  surface	  with	   the	  aim	  of	  debriding	   the	  adhered	  biofilm	  and	  to	  reduce	  the	  bacterial	  
load	   below	   the	   threshold	   level	   for	   disease	   (64).	   Mechanical	   debridement	   around	   dental	  
implants	   presents	   some	   specific	   characteristics:	   the	   absence	   of	   periodontal	   ligament,	   a	  
variable	  (more/less	  rough)	  implant	  surface	  and	  different	  types	  of	  abutment	  connection.	  All	  
these	   factors	   can	   jeopardize	   not	   only	   the	   professional	   therapy,	   but	   also	   patient’s	   self-­‐
performed	   hygiene,	   since	   these	   characteristics	   may	   facilitate	   biofilm	   formation	   when	   the	  
surfaces	  get	  exposed	  to	  the	  oral	  environment	  (34).	   In	  order	  to	  overcome	  these	  limitations,	  
different	  protocols	  combining	  adjunctive	  treatments	  have	  been	  proposed:	  	  
	  
Peri-­‐implantitis	  non-­‐surgical	  therapy:	  mechanical	  or	  automatic	  debridement	  	  
Similar	   objectives	   and	   technologies	   for	   the	   mechanical	   debridement	   of	   implant	   surfaces	  
(curettes,	   air-­‐abrasive	   devices,	   ultrasonic	   devices,	   lasers)	   have	   been	   evaluated	   for	   the	  
treatment	   of	   peri-­‐implantitis,	   with	   the	   main	   difference	   that	   they	   are	   aimed	   more	  
subgingivally	  to	  decontaminate	  the	  exposed	  implant	  surfaces.	  	  
	  
In	   regards	   to	   the	   use	   of	   curettes	   for	   scaling	   implant	   surfaces,	   the	   same	   considerations	  
described	   for	   the	   treatment	   of	   peri-­‐implant	   mucositis	   are	   valid	   for	   the	   non-­‐surgical	  
treatment	   of	   peri-­‐implantitis.	   Different	   types	   of	   curettes	   have	   been	   studied,	  mainly	   those	  
made	  of	   carbon	   fibre	   (15)	   or	   titanium	   (25,	   37,	   44)	   and	  most	   of	   the	   protocols	   included	   an	  
adjunctive	  polishing	  with	  rubber	  cup	  and	  polishing	  paste.	  
	  
Standard	  powdered	  air	  abrasive	  systems	  are	  based	  on	  the	  air-­‐spray	  of	  sodium	  bicarbonate.	  
They	   are	   used	   for	   polishing	   and	   removing	   tooth	   stains,	   but	   cannot	   be	   used	   for	   implant	  
instrumentation	   since	   they	   may	   cause	   hard	   and	   soft	   tissue	   damage	   due	   to	   their	   high	  
abrasiveness	  (17).	  Recently,	  a	  powered	  air	  abrasive	  system	  based	  on	  a	  low	  abrasive	  amino-­‐
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acid	  glycine	  powder	  (Figure	  9)	  has	  demonstrated	  to	  effectively	  remove	  biofilm	  from	  the	  root	  
surface,	   without	   damaging	   hard	   and	   soft	   tissues	   (27)	   and	   it	   has	   been	   recommended	   for	  
debriding	   implant	   surfaces.	   It	  uses	  a	   specially	  designed	  nozzle,	   consisting	  of	  a	   thin	   flexible	  
plastic	   tube	   (length:	   1.7	   cm;	   diameter:	   0.8	   mm	   at	   the	   tip)	   that	   is	   fitted	   with	   three	  
orthogonally	  orientated	  holes.	  This	  specific	  design	  is	  associated	  with	  a	  horizontal	  exit	  of	  the	  
air	  powder	  mixture	  and	  a	   reduced	  pressure,	   thus	  preventing	  emphysema	  formation	   in	   the	  
adjacent	   tissue.	   The	  hand	  piece	   (Air-­‐	   Flows	   EL-­‐308/A,	   EMS)	   should	   be	   guided	   in	   a	   circular	  
motion	  from	  coronal	  to	  apical	  parallel	  to	  the	  implant	  surface	  in	  a	  noncontact	  mode	  and	  the	  
instrumentation	  time	  at	  each	  aspect	  (i.e.	  mesial,	  distal,	  vestibular	  and	  oral)	  should	  be	  limited	  
to	  5	  seconds,	  as	  recommended	  by	  the	  manufacturer	  (42).	  It	  has	  also	  been	  described	  to	  place	  
the	  nozzle	   in	   the	  pocket	  mesially,	   lingually,	  distally	  and	  buccally,	  approximately	   for	  15	  s	   in	  
each	  position.	  Circumferences	  should	  be	  done	  around	  the	  implant,	  attempting	  to	  cover	  the	  
entire	  exposed	  implant	  surface	  (33,	  44).	  
	  
Similar	   to	   curettes	   and	   air	   abrasive	   devices,	   ultrasonic	   devices	   in	   the	   treatment	   of	   peri-­‐
implantitis	  are	  aimed	  to	  effectively	  remove	  biofilm	  and	  calculus	  without	  altering	  the	  implant	  
surface.	  To	  accomplish	  this,	  different	  tip	  modifications	  have	  been	  proposed,	  such	  as	  carbon	  
fiber,	   silicone	   or	   plastic	   (15,	   25,	   37).	   Another	  modification	   to	   the	   conventional	   ultrasonic	  
device	   is	   the	   Vector®	   system	   (Dürr	   Dental,	   Bietigheim-­‐Bissingen,	   Germany),	   where	   the	  
horizontal	  vibration	  is	  converted	  by	  a	  resonating	  ring	  into	  a	  vertical	  vibration,	  resulting	  in	  a	  
parallel	  movement	  of	  the	  working	  tip	  to	  the	  surface.	  	  
	  
The	   use	   of	   lasers	   has	   been	   proposed	   in	   the	   treatment	   of	   peri-­‐implantitis	   due	   to	   its	   anti-­‐
infective,	  physical	  and	  ablation	  properties.	  The	  Er:YAG	  laser	  technology	  (Figure	  10)	  is	  the	  one	  
that	  has	  shown	  the	  highest	  potential	  for	  use	  in	  the	  treatment	  of	  peri-­‐implantitis,	  due	  to	  its	  
efficacy	   to	   remove	   subgingival	   plaque	   and	   calculus	   without	   significantly	   damaging	   the	  
implant	   surface	   (59).	   This	   laser	   is	   used	   for	   peri-­‐implantitis	   treatment	  with	   a	   special	   hand-­‐
piece	   containing	   a	   cone-­‐shaped	   sapphire	   tip,	   which	   should	   be	   used	   in	   a	   parallel	   and	  
semicircular	  motion	  around	  the	  circumference	  of	  the	  pocket.	  The	  laser	  should	  be	  set	  with	  an	  
energy	  of	  100	  mJ	  and	  a	  frequency	  of	  10	  Hz	  (24,	  33,	  50,	  56).	  Recently	  a	  protocol	  combining	  a	  
diode	  laser	  with	  a	  wavelength	  of	  660	  nm	  and	  a	  power	  density	  of	  100	  mW	  during	  10	  seconds	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in	  each	  pocket	  the	  use	  of	  the	  dye	  phenothiazine	  chloride	  for	  3	  minutes	  followed	  by	  irrigation	  
with	  3%	  hydrogen	  peroxide	  has	  been	  proposed	  (44)	  
	  
All	  the	  debridement	  systems	  described	  above	  can	  be	  combined	  to	  obtain	  a	  better	  removal	  of	  
biofilm	   and	   calculus:	   the	   combination	   of	   sodium	   carbonate	   air-­‐powder	   and	   resin	   curettes	  
has	  been	  evaluated	  (9).	  
	  
Peri-­‐implantitis	  non-­‐surgical	  therapy:	  adjunctive	  use	  of	  antimicrobial	  products	  
Adjunctive	  therapies	  such	  as	  antibiotics	  and	  antiseptics	  have	  been	  proposed	  to	  improve	  the	  
results	   of	   non-­‐surgical	   debridement	   since	   the	   reduction	   of	   the	   bacterial	   loads	   to	   levels	  
compatible	  with	  tissue	  health	  is	  difficult	  to	  accomplish	  with	  mechanical	  means	  alone	  (36).	  	  
	  
Chlorhexidine-­‐based	  products	  as	  gels,	  irrigation	  and/or	  rinses	  in	  different	  formulations	  and	  
regimes	  have	  been	  reported,	  such	  as:	  a)	  repeated	  irrigation	  of	  the	  peri-­‐implant	  pocket	  with	  
CHX	  0.2%	  in	  one	  session	  (4);	  b)	  single	  application	  of	  CHX	  gel	  1%	  with	  a	  disposable	  syringe	  (30,	  
32);	   c)	   repeated	  application	  of	  CHX	  gel	  1%	  at	   treatment	  and	  30	  and	  90	  days	  after	   (31);	  d)	  
combination	  of	  pocket	   irrigation	  with	  CHX	  0.2%	  plus	  CHX	  gel	  0.2%	  applied	  subgingivally	   in	  
each	  implant	  	  at	  the	  day	  of	  intervention	  and	  CHX	  mouth	  rinse	  0.2%	  twice	  daily	  for	  two	  weeks	  
(50,	  56);	  e)	  and	  pocket	  irrigation	  with	  CHX	  0.12%	  plus	  CHX	  gel	  1%	  (42).	  
	  
Different	   protocols	   have	   been	   evaluated	   using	   locally	   or	   systemically	   delivered	  
antimicrobials:	  a)	  single-­‐unit	  dose	  of	  1	  mg	  minocycline	  and	  3	  mg	  poly-­‐glycolide-­‐co-­‐dl-­‐lactide	  
placed	  submucosally	  per	  treatment	  site,	  at	  treatment	  time	  and	  30	  and	  90	  days	  after	  (31);	  b)	  
a	  unique	  dose	  of	  1	  mg	  minocycline	  microspheres	  (30,	  44);	  c)	   	  minocycline	  microspheres	  at	  
treatment	   time	   and	   180	   and	   270	   days	   after	   (43);	   d)	   or	   topical	   irrigation	   with	   a	   solution	  	  
containing	  8.5%	  by	  weight	  of	  doxycycline	  and	  37%	  by	  weight	  of	  poly	  d,l-­‐lactide	  dissolved	  in	  a	  
biocompatible	   carrier	   of	   N	   -­‐methyl-­‐2-­‐pyrrolidone	   (4).	   Systemic	   antibiotics	   have	   been	   also	  
used,	  but	  there	  are	  not	  controlled	  clinical	  trials	  evaluating	  their	  effect.	  
	  
Peri-­‐implantitis	  non-­‐surgical	  therapy:	  evaluation	  in	  controlled	  trials	  
At	  least	  nine	  controlled	  trials,	  reported	  in	  thirteen	  articles,	  have	  evaluated	  the	  non-­‐surgical	  
therapy	   of	   peri-­‐implantitis.	   Although	   the	   same	   case	   definition	   for	   peri-­‐implantitis	  was	   not	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used	   in	   all	   studies,	   all	   included	   BOP	   of	   the	   peri-­‐implant	   mucosa,	   increased	   PPD	   and	  
radiographic	   bone	   loss.	   The	   sample	   size	   ranged	   between	   18-­‐42	   patients	   and	   the	   mean	  
follow-­‐up	  varied	  between	  3	  to	  12	  months.	  	  
	  
Different	  treatment	  protocols	  were	  evaluated	  that	  can	  be	  grouped	  in	  three	  categories:	  
• Antimicrobials.	  Mechanical	  debridement	  was	  performed	  with	   the	  adjunctive	  use	  of	  
an	  antiseptic	  or	  a	  locally	  delivery	  antibiotic	  (4,	  30,	  31,	  42,	  44).	  
• Lasers.	   Two	   types	   of	   lasers	   were	   compared	   to	   different	   protocols	   of	   mechanical	  
debridement	  (24,	  33,	  44,	  50,	  56).	  
• Ultrasonic	  devices.	  Vector®	  system	  was	  compared	  to	  two	  different	  types	  of	  curettes	  
(15,	  25,	  37)	  	  
	  
Efficacy	   was	   evaluated	   by	   means	   of	   PPD	   and	   BOP	   reductions	   as	   the	   main	   outcome	  
measurements.	   As	   secondary	   outcome	   variables,	   changes	   in	   PI,	   clinical	   attachment	   level	  
(CAL),	   microbiological	   outcomes	   and	   radiographic	   bone	   level	   changes	   were	   used	   in	   some	  
studies.	  	  
	  
Based	  on	  the	  effect	  on	  these	  clinical	  outcomes	  we	  can	  draw	  the	  following	  conclusions,	  with	  
regards	  to	  the	  adjunctive	  use	  of	  antimicrobials:	  	  
• Three	  publications	  reported	  results	  of	  the	  same	  study,	  with	  variations	  in	  the	  follow-­‐
up	  (3-­‐12	  months)	  and	  in	  the	  type	  of	  analysis	  (patient-­‐	  or	  implant-­‐based)	  (30,	  31,	  44).	  
They	   compared	   the	   use	   of	   carbon-­‐fibre	   curettes	   plus	   CHX	   gel	   versus	   carbon-­‐fibre	  
curettes	  plus	   locally	   delivered	  minocycline,	   and	   reported	  a	   very	   small	   added	  effect	  
with	  the	  use	  of	  minocycline	  both	  on	  PPD	  (0-­‐0.15	  mm	  in	  the	  CHX	  group,	  0.3-­‐0.4	  mm	  in	  
the	  minocycline	  group)	  and	  BOP	   (8-­‐38%	   in	   the	  CHX	  and	  16-­‐26%	   in	   the	  minocycline	  
group).	   Interestingly,	   authors	   observed	   that	   when	   repeating	   the	   minocycline	  
application	  in	  residual	  pockets,	  the	  results	  were	  much	  better	  (31).	  
• In	  the	  second	  subgroup,	  plastic	  curettes	  alone	  were	  compared	  to	  plastic	  curettes	  plus	  
the	  adjunctive	  use	  of	  locally	  delivered	  doxycycline	  (4).	  After	  a	  mean	  follow-­‐up	  period	  
of	  4.5	  months,	  changes	  in	  PPD	  and	  BOP	  were	  only	  significant	  in	  the	  antibiotic	  group.	  
While	  the	  control	  group	  had	  a	  mean	  reduction	  in	  PPD	  of	  0.28	  mm	  and	  in	  BOP	  of	  13%,	  
the	  experimental	  group	  experienced	  a	  reduction	  of	  1.15	  mm	  and	  27%,	  respectively.	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• In	  the	  last	  subgroup,	  carbon-­‐fibre	  curettes	  plus	  CHX	  irrigation	  and	  gel	  application	  was	  
compared	  to	  a	  glycine-­‐based	  powder	  air-­‐abrasive	  (42).	  After	  6	  months	  of	  follow-­‐up,	  
both	  groups	  reduced	  similarly	  PPD	  (0.5	  mm	  in	  the	  CHX	  group	  and	  0.6	  mm	  in	  the	  air-­‐
abrasive	   group),	   although	   BOP	   was	   more	   reduced	   in	   the	   air-­‐abrasive	   group	   (43%	  
versus	  11%,	  respectively).	  
	  
Based	   on	   these	   results,	   locally	   delivered	   antibiotics	   may	   provide	   an	   extra	   clinical	   benefit	  
when	   compared	   to	   CHX,	   especially	   when	   repeated	   applications	   are	   administered.	  
Nevertheless,	  data	  should	  be	  analysed	  carefully,	  since	  the	  clinical	  effect	  was	  limited.	  
	  
With	  regards	  to	  the	  evaluation	  of	  lasers,	  the	  following	  conclusions	  were	  reported:	  
• In	  the	  group	  of	  lasers,	  two	  types	  of	  lasers	  have	  been	  studied,	  Er:YAG	  and	  diode	  lasers,	  
although	   the	   vast	  majority	   of	   the	   research	   has	   focused	   on	   Er:YAG	   lasers.	   In	   a	   first	  
group	   of	   studies,	   Er:YAG	   laser	   was	   compared	   to	   conventional	   debridement	   with	  
plastic	  curettes	  and	  subgingival	  irrigation	  with	  CHX	  (50,	  56).	  It	  was	  reported	  that	  up	  
to	  the	  6	  months	  evaluation,	  the	  Er:YAG	  laser	  obtained	  higher	  PPD	  and	  BOP	  reduction	  
than	  the	  conventional	  debridement,	  but	  after	  12	  months	  both	  groups	  experienced	  a	  
relapse	  in	  the	  clinical	  benefits	  previously	  obtained,	  although	  this	  rebound	  was	  higher	  
in	   the	   control	   group.	   Therefore,	   it	   can	   be	   stated	   that	   Er:YAG	   laser	   improved	   the	  
clinical	   outcomes	   but	   not	   	   enough	   to	   control	   peri-­‐implant	   infection	   one	   year	   after	  
therapy.	  
• A	  second	  group	  of	  studies	  analysed	  the	  clinical	  and	  microbiological	  effect	  of	  Er:YAG	  
laser	  compared	  to	  glycine-­‐based	  air-­‐abrasive	  (24,	  33).	  After	  a	  6	  month-­‐period,	  both	  
groups	  significantly	  reduced	  PPD,	  without	  differences	  between	  groups	  (0.9	  mm	  in	  the	  
air-­‐abrasive	  group	  and	  0.8	  mm	  in	  the	  laser	  group).	  Data	  for	  BOP	  values	  showed	  that	  
while	   the	   laser	  group	  had	  31%	  of	   sites	   free	  of	  bleeding,	   the	  air-­‐abrasive	  group	  had	  
25%	   of	   sites	   free	   of	   bleeding	   (33).	   For	   the	  microbiological	   outcomes,	   it	  was	   found	  
that	   none	   of	   the	   groups	   could	   reduce	   bacterial	   counts	   at	   6	   months	   and	   that	  
Porphyromonas	   gingivalis	   counts	   were	   higher	   in	   cases	   with	   progressive	   peri-­‐
implantitis	  (24).	  	  	  
• The	  diode	  laser	  has	  been	  used	  in	  combination	  with	  photodynamic	  therapy	  and	  locally	  
delivery	  minocycline	  after	  initial	  mechanical	  debridement	  with	  titanium	  curettes	  and	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glycine-­‐based	  air-­‐abrasive	   (44).	   	  At	   the	  3-­‐month	   visit,	   both	   groups	  had	   significantly	  
reduced	   PPD	   and	   BOP,	   although	   no	   further	   changes	   could	   be	   seen	   up	   to	   the	   6	  
months	   follow-­‐up.	  No	  differences	   could	  be	   seen	  between	  groups	   for	  PPD	  and	  BOP	  
reduction	  at	  any	  time	  point.	  Nevertheless,	  at	  the	  end	  of	  the	  study,	  the	  photodynamic	  
group	  had	  double	  of	  cases	  with	  complete	  resolution	  of	  the	  inflammation	  (30%	  versus	  
15%).	  
	  
Based	   on	   these	   results,	   the	   use	   of	   lasers	   could	   provide	   short-­‐term	   clinical	   benefits	   in	   the	  
non-­‐surgical	   treatment	   of	   peri-­‐implantitis	   (up	   to	   3	   months).	   Nevertheless,	   we	   have	   to	  
carefully	  analyse	  the	  cost-­‐benefits	  of	  this	  therapy,	  since	  the	  results	  were	  similar	  to	  the	  ones	  
obtained	  with	  easier	  and	  cheaper	  technologies.	  
	  
And	   finally,	  with	  regards	   to	   the	  evaluation	  of	  ultrasonic	   devices,	   the	   following	  conclusions	  
were	   taken:	   the	   Vector®	   system	   was	   compared	   to	   carbon-­‐fibre	   (15)	   or	   titanium	   (25,	   37)	  
curettes	  after	  6	  months	  of	  follow-­‐up.	   It	  was	  observed	  that	  carbon-­‐fibre	  curettes	  had	  a	  null	  
effect	   on	   PPD	   reduction	   with	   an	   increase	   in	   BOP.	   In	   the	   other	   hand,	   the	   Vector®	  system	  
could	   not	   reduce	   PPD	   but	  was	   able	   to	   reduce	   BOP	   from	   63%	   to	   36%	   (15).	   In	   the	   case	   of	  
titanium	  curettes,	  authors	  could	  not	  find	  neither	  intra-­‐	  nor	  inter-­‐group	  differences	  for	  PPD,	  
BOP	  changes	  (37)	  or	  in	  microbiological	  outcomes	  (25).	  Therefore,	  we	  can	  conclude	  that	  this	  
technology	   was	   ineffective	   in	   resolving	   peri-­‐implantitis	   and	   had	   a	   very	   small	   effect	   in	  
mucosal	  inflammation.	  
	  
Peri-­‐implantitis	  non-­‐surgical	  therapy:	  summary	  and	  conclusions	  
Several	   protocols	   have	   been	   reported	   for	   the	   non-­‐surgical	   treatment	   of	   peri-­‐implantitis.	  
They	   usually	   involved	   the	   mechanical	   debridement	   of	   the	   implant	   surface	   by	   means	   of	  
curettes	   (4,	  15,	  25,	  30,	  31,	  37,	  42,	  44,	  50,	  56),	  ultrasonic	  devices	   (15,	  25,	  37),	   air-­‐abrasive	  
devices	   (24,	  33,	  42,	  44);	  or	   lasers	   (24,	  33,	  44	   ,	  50,	  56),	  combined	  or	  not	  with	  some	  sort	  of	  
chemical	  action	  mainly	  based	  on	  local	  antibiotics	  (4,	  30,	  31,	  44)	  	  or	  antiseptics	  such	  as	  CHX	  
(30,	  31,	  42,	  44,	  50,	  56).	  	  
	  
The	  analyses	  on	   the	  efficacy	  of	   these	  protocols	   in	   controlled	   trials	   revealed	  a	   very	   limited	  
effect	  in	  terms	  of	  the	  surrogate	  outcome	  PPD,	  while	  the	  effect	  on	  BOP	  was	  more	  significant.	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Out	  of	  the	  thirteen	  selected	  studies,	  the	  largest	  PPD	  reduction	  was	  1.2	  mm	  (4)	  and	  final	  BOP	  
scores	  were	  almost	   in	  all	   the	  papers	  greater	   than	  50%.	   In	  addition,	   this	   treatment	  did	  not	  
provide	   changes	   in	   the	   bone	   levels.	   On	   the	   other	   hand,	   it	   is	   also	   important	   to	   consider	  
important	  limiting	  factors	  in	  these	  studies,	  such	  as	  the	  limited	  follow	  up	  (only	  12-­‐month	  data	  
is	  currently	  available),	  reduced	  sample	  sizes	  and	  the	  lack	  of	  a	  defined	  control	  group.	  	  
	  
Based	  on	  the	  available	  data,	  it	  seems	  that	  the	  non-­‐surgical	  therapy	  of	  peri-­‐implantitis	  is	  not	  
effective	   in	   disease	   resolution,	   since	   only	   limited	   improvements	   in	   the	   main	   clinical	  
parameters	  are	  reported	  and	  there	  is	  a	  clear	  tendency	  for	  disease	  recurrence.	  It	  is	  therefore	  
recommended	   to	   consider	   advanced	   therapies,	   such	   as	   surgical	   interventions,	   when	   non-­‐
surgical	  peri-­‐implant	  surgery	  is	  unable	  to	  significantly	  improve	  the	  clinical	  parameters.	  	  	  
	  
	  
Peri-­‐implantitis	  surgical	  therapy	  
As	   described	   before,	   non-­‐surgical	   treatment	   of	   peri-­‐implant	   diseases	   have	   shown	  modest	  
efficacy	  and	  one	  possible	  explanation	  for	  these	  limited	  results	  may	  be	  related	  to	  a	  defective	  
decontamination	  of	  the	  implant	  surface	  exposed	  to	  bacterial	  biofilms.	  Indeed,	  the	  geometry	  
of	  the	  threads	  and	  the	  modification	  of	  the	  implant	  surface	  may	  complicate	  the	  cleansibility	  
when	  bone	  loss	  occurs	  and	  the	  exposed	  implant	  surfaces	  are	  exposed	  to	  bacterial	  biofilms,	  
especially	   rough	   surfaces	   (34).	  Moreover,	   the	  histopathology	  of	   the	  peri-­‐implant	   lesions	   is	  
characterized	   by	   presence	   of	   an	   inflammatory	   cell	   infiltrate	   extending	   apically	   in	   direct	  
contact	  with	   the	   bone	   crest	   and	   leading	   to	   loss	   of	   osseointegration	   (3).	   In	   addition,	   peri-­‐
implantitis	  has	  been	  associated	  to	  a	  Gram-­‐negative	  anaerobic	  microbiota,	  similar	  to	  severe	  
periodontitis	   around	   natural	   teeth,	   which	   might	   be	   difficult	   to	   control	   with	   non-­‐surgical	  
therapy	  alone	  (36).	  	  
	  
As	  an	  additional	  objective	  to	  the	  treatment	  of	  peri-­‐implant	  infection,	  the	  treatment	  of	  peri-­‐
implantitis	  should	  aim	  for	  bone	  regeneration	  and	  the	  attainment	  of	  re-­‐osseointegration.	  This	  
phenomenon	   of	   direct	   bone	   to	   implant	   contact	   on	   a	   previously	   contaminated	   implant	  
surface	   has	   been	   documented	   in	   pre-­‐clinical	   models,	   although	   never	   demonstrated	   in	  
humans	   (23,	   26).	   It	   is	   therefore,	   the	   rationale	  of	   the	   surgical	   treatment	  of	   peri-­‐implantitis	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two-­‐fold:	  to	   improve	   implant	  surface	  cleanability	  and	  to	  modify	  soft	  and	  hard	  peri-­‐implant	  
tissues	  anatomy	  in	  order	  to	  obtain	  re-­‐osseointegration.	  
	  
Peri-­‐implantitis	  surgical	  therapy:	  decontamination	  of	  implant	  surface	  
When	  the	  implant	  surface	  is	  exposed	  to	  oral	  biofilms,	  it	  becomes	  contaminated	  and,	  in	  order	  
to	  promote	  healing,	  a	  decontamination	  of	  the	  surface	  is	  mandatory.	  Numerous	  approaches	  
have	  been	  used	  for	  implant	  surface	  decontamination	  during	  peri-­‐implant	  surgery,	  including	  
mechanical,	  chemical	  or	  laser	  treatments.	  	  
	  
Mechanical	  decontamination	  	  
It	   consists	   of	   the	   physical	   removal	   of	   hard	   and	   soft	   tissue	   deposits	   on	   the	   contaminated	  
exposed	  implant	  surface.	  Instruments	  for	  mechanical	  debridement	  usually	  include	  curettes,	  
ultrasonic	   devices	  with	   special	   tips	   and	   air-­‐powder	   abrasive	   systems.	   The	   advantages	   and	  
limitations	  of	  these	  systems	  have	  already	  been	  described	  when	  used	  in	  non-­‐surgical	  therapy	  
(33).	  
	  
A	  second,	  and	  more	  aggressive	  approach	  has	  been	  proposed,	  consisting	  on	  the	  smoothening	  
of	  the	  implant	  surface	  eliminating	  the	  rough	  implant	  surface	  resulting	  in	  a	  polished	  smooth	  
surface	  more	  amenable	  for	  oral	  hygiene	  practices.	  This	  procedure	  termed	  “implantoplasty”	  
(38)	  is	  carried	  out	  with	  burs	  and	  stones	  under	  copious	  irrigation,	  since	  there	  is	  an	  important	  
rise	  in	  temperature	  extensive	  local	  contamination	  with	  titanium	  (61).	  	  
	  
Chemical	  decontamination	  
The	  rationale	  of	  chemical	  treatments	  is	  to	  apply	  substances	  directly	  on	  the	  implant	  surface	  
for	  its	  desinfection/decontamination.	  Citric	  acid,	  hydrogen	  peroxide,	  CHX	  and/or	  saline	  have	  
been	  utilized	  all	  providing	  similar	  results	  in	  experimental	  studies	  (16)	  (46).	  	  
	  
Lasers	  
Lasers	   have	   also	   been	   used	   to	   decontaminate	   the	   implant	   surface,	   although	   scientific	  
literature	  often	  failed	  to	  find	  clinical	  benefits.	  Schwarz	  and	  co-­‐workers	  noticed	  that	  erbium	  
lasers	  were	   able	   to	  determine	   significant	   advantages	   in	   terms	  of	   bleeding	  on	  probing	   and	  
clinical	   attachment	   level,	   however	   no	   differences	   were	   noticed	   when	   compared	   to	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conventional	   mechanical	   treatment	   (53).	   No	   differences	   between	   laser	   and	   conventional	  
treatment	  were	  also	  noted	  with	  a	  CO2	  laser	  as	  adjunct	  to	  both	  resective	  and	  reconstructive	  
technique	  (8).	  
	  
Peri-­‐implantitis	  surgical	  therapy:	  surgical	  techniques	  
Various	  surgical	  techniques	  have	  been	  recommended	  depending	  on	  the	  final	  objective	  of	  the	  
surgical	  intervention:	  a)	  access	  for	  cleaning	  and	  decontaminating	  the	  implant	  surface	  (access	  
flaps);	   b)	   access	   for	   cleaning	   and	  decontamination	  plus	   exposing	   the	   affected	   surfaces	   for	  
cleaning	   (apically	   repositioned	   flaps);	   and	   c)	   access	   for	   cleaning	   plus	   aiming	   for	   bone	  
regeneration	  and	  re-­‐osseointegration	  (regenerative	  techniques)	  	  	  
	  
Access	  Flap	  Surgery	  
The	   objective	   of	   this	   flap	   surgical	   intervention	   is	   to	   conserve	   and	   to	  maintain	   all	   the	   soft	  
tissues	   around	   the	   affected	   implant	   and	   to	   focus	   mainly	   on	   the	   decontamination	   of	   the	  
implant	  surface.	  Usually,	  intracrevicular	  incisions	  (Figure	  11a)	  are	  made	  around	  the	  affected	  
implants	  and	  mucoperiostal	  flaps	  are	  raised	  both	  buccally	  and	  palatally/lingually	  (Figure	  11b).	  
Degranulation	   of	   the	   peri-­‐implant	   inflamed	   tissues	   is	   best	   accomplished	   with	   titanium	  
curettes	  and	  finally	  implant	  surface	  decontamination	  is	  performed	  with	  one	  of	  the	  methods	  
previously	  described.	  Finally,	  the	  flaps	  are	  repositioned	  and	  adequately	  sutured	  (Figure	  11c).	  
Since	   there	   is	   no	   evidence	   from	   human	   or	   animal	   studies	   that	   implant	   surface	  
decontamination	  alone	  may	  result	   in	  re-­‐osseointegration,	  this	  surgical	   intervention	  aims	  to	  
eliminate	  the	  inflammatory	  changes	  responsible	  of	  the	  disease	  process.	  Since	  this	  technique	  
aims	   to	  maintain	   the	  position	  of	   the	   soft	   tissue	  margin	   around	   the	   implant	   neck,	   this	   can	  
only	  be	  attained	  when	  the	  peri-­‐implant	  bone	  loss	  is	  shallow.	  	  	  	  
	  
Apically	  positioned	  flaps	  
This	  surgical	  approach	  has	  been	  advocated	  in	  order	  to	  enhance	  self-­‐performed	  oral	  hygiene	  
and	   reduce	   the	   pockets	   around	   affected	   implants	   (20).	   Technically,	   a	   reverse	   beveled	  
incision	  is	  designed	  depending	  on	  the	  probing	  pocket	  depth	  and	  the	  width	  and	  the	  thickness	  
of	  the	  peri-­‐implant	  mucosa	  	  (Figure	  12a).	  Vertical	  releasing	  incisions	  may	  be	  needed	  in	  order	  
to	   apically	   position	   the	   flap.	   Mucoperiostal	   flaps	   are	   raised	   both	   buccally	   and	  
palatally/lingually	   (Figure	  12b).	   	  The	  collar	  of	  affected	  tissues	   is	  then	  removed	  and	   implant	  
	   20	  
surfaces	  are	  thoroughly	  decontaminated.	  Often	  osteoplasty,	  carefully	  performed	  with	  bone	  
chisels,	  is	  needed.	  Finally,	  flaps	  are	  sutured	  in	  order	  to	  leave	  the	  previously	  affected	  part	  of	  
the	  implant	  exposed	  to	  the	  oral	  cavity	  (Figure	  12c).	  In	  order	  to	  smoothen	  the	  exposed	  part	  
and	  to	  decrease	  the	  post-­‐surgical	  contamination	  of	  the	  implant	  surface,	  implantoplasty	  has	  
been	   suggested	   (38).	   This	   technique	  may	   be	   indicated	   for	   peri-­‐implantitis	  with	   suprabony	  
defects	   or	   one-­‐wall	   intrabony	   defect.	   It	   is	   obviously	   a	   technique	   chosen	   mainly	   for	   non-­‐
aesthetical	  areas	  (39).	  
	  
Regenerative	  surgical	  techniques	  
Regenerative	  approaches	  have	  two	  main	  objectives:	  	  
• to	   support	   the	   tissues	   dimension	   during	   the	   healing	   process,	   avoiding	   recession	   of	  
the	  mucosa.	  
• to	   enhance	   the	   chance	   of	   obtaining	   re-­‐osseointegration,	   using	   reconstructive	   and	  
regenerative	  techniques/materials.	  	  
	  
In	  this	  technique,	  intracrevicular	  incisions	  are	  often	  performed	  in	  order	  to	  maintain	  the	  total	  
amount	   of	   soft	   tissues	   (Figure	   13a).	   After	   elevation	   of	   buccal	   and	   lingual	   periosteal	   flaps,	  
degranulation	  of	  the	  defect	  is	  performed	  with	  titanium	  instruments.	  After	  decontamination	  
of	  the	  implant	  surface,	  a	  graft	  is	  placed	  around	  the	  implant,	  filling	  the	  intrabony	  component	  
of	  the	  defect	  (Figure	  13b).	  Grafting	  may	  be	  performed	  with	  either	  autologous	  bone	  (16)	  or	  
bone	   substitutes	   (52).	   The	   graft	   may	   be	   covered	   (Figure	   13c)	   with	   a	   resorbable	   or	   non-­‐
resorbable	  membrane	  (16,	  41).	  Finally,	  flaps	  are	  coronally	  positioned	  and	  sutured	  in	  order	  to	  
determine	  healing	  (Figure	  13d),	  either	  with	  a	  non-­‐submerged	  or	  a	  submerged	  approach	  (1).	  	  
	  
A	   combined	   regenerative	   and	   resective	   approach	   has	   also	   been	   proposed	   (53),	   including	  
extensive	   implantoplasty	   in	   the	   suprabony	   component	   of	   the	   defect;	   conversely,	   for	   the	  
intrabony	   component,	   two	   procedures	   of	   decontamination	   were	   compared,	   namely	   an	  
Er:YAG	  laser	  or	  plastic	  curettes	  and	  sterile	  saline.	  This	  technique	  is	  based	  on	  the	  knowledge	  
that	  the	  most	  common	  peri-­‐implant	  defects	  normally	  include	  an	  intrabony	  component	  and	  a	  
more	  coronal	  supra-­‐bony	  portion.	  The	  intrabony	  component	  of	  the	  defect	  was	  treated	  with	  
a	   collagen	   membrane	   and	   a	   bovine	   xenograft	   (53)	   and	   the	   supra-­‐bony	   component	   with	  
resective	  surgery.	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Peri-­‐implantitis	  surgical	  therapy:	  evaluation	  in	  controlled	  trials	  
There	   are	   a	   limited	   number	   of	   controlled	   studies	   evaluating	   the	   surgical	   therapy	   of	   peri-­‐
implantitis,	  and	  they	  are	  small	  in	  	  sample	  size,	  limited	  follow	  up	  and	  high	  risk	  of	  biases	  (11).	  
Moreover,	  the	  evaluation	  of	  efficacy	  is	  hampered	  by	  the	  lack	  of	  a	  standard	  mode	  of	  therapy,	  
and	   therefore,	   there	   is	   no	   clear	   control	   therapy.	   In	   fact,	   study	   designs	   comparing	   non-­‐
surgical	   treatment	  versus	  open	  flap	  debridement	  or	  open	  flap	  debridement	  versus	  apically	  
repositioned	  flaps	  are	  lacking.	  
	  
Reported	  studies	  can	  be	  grouped	  in	  three	  categories	  according	  to	  their	  main	  objective:	  
• to	  compare	  different	  methods	  of	   implant	  surface	  decontamination,	  while	  using	   the	  
same	  surgical	  approach	  such	  as	  resective,	  reconstructive	  or	  mixed	  (8,	  38,	  51,	  53).	  	  
• to	  compare	  grafting	  peri-­‐implant	  bony	  defects	  with	  or	  without	  a	  membrane	  (16,	  41).	  
• to	  compare	  two	  different	  types	  of	  reconstructive	  surgery	  (48,	  52).	  
	  
As	  discussed	  in	  the	  non-­‐surgical	  therapy	  section,	  clinical	  conclusions	  are	  drawn	  based	  on	  the	  
results	   from	   surrogate	   periodontal	   outcomes.	   The	   validity	   of	   these	   surrogates	   has	   been	  
extensively	   studied	   in	   Periodontology	   but	   it	   is	   not	   clear	   whether	   their	   utility	   is	   similar	   in	  
implant	   dentistry.	   Indeed,	   few	   papers	   have	   provided	   information	   on	   true	   end-­‐point	  
outcomes	  (peri-­‐implantitis	  resolution)	  and	  none	  in	  regards	  to	  the	  evaluation	  of	  the	  surgical	  
treatment	  of	  peri-­‐implant	  diseases	  (14,	  33).	  	  
In	   spite	   of	   these	   limitations	   and	   based	   on	   the	   results	   from	   surrogate	   outcomes,	   different	  
conclusions	  can	  be	  drawn:	  
• When	  comparing	  apically	   repositioned	   flaps	  with	  and	  without	   implantoplasty,	   after	  
24	   months,	   groups	   treated	   with	   implantoplasty	   demonstrated	   significant	  
improvements	   in	   regards	   to	   PPD	   and	   CAL	   levels	   (38).	   Another	   study	   (8)	   compared	  
decontamination	  with	  air	  powder	  abrasion	  versus	  CO2	  laser,	  used	  during	  resective	  or	  
reconstructive	   surgery	   (with	   a	   mixture	   beta-­‐tricalcium	   phosphate	   and	   autologous	  
bone),	   demonstrating	   no	   significant	   differences	   between	   the	   four	   groups	   at	   the	  
short-­‐term	   evaluation.	   However,	   in	   longer	   follow-­‐ups,	   laser	   decontamination	   and	  
soft	  tissue	  resection	  showed	  the	  highest	  performance	  whereas	  no	  differences	  were	  
noted	   among	   air	   abrasion	   and	   laser	   treatment	   when	   reconstructive	   surgery	   was	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performed.	   A	   third	   study	   (53)	   reported	   no	   differences	   in	   terms	   of	   peri-­‐implant	  
bleeding	  or	  clinical	  attachment	   levels,	  at	  6	  months,	  between	  decontamination	  with	  
plastic	   curettes	   and	   saline	   versus	   Er:Yag	   laser,	   after	   extensive	   implantoplasty,	   and	  
treatment	   of	   the	   intrabony	   component	   with	   bovine	   xenograft	   and	   collagen	  
membrane.	  	  
• In	   reconstructive	   approaches,	   an	   important	   conclusion	  was	   the	   lack	   of	   differences	  
whether	   or	   not	   to	   use	   a	   resorbable	   membrane.	   With	   reconstructive	   surgery	   with	  
autogenous	   bone	   grafting	   and	   decontamination	   with	   CHX,	   citric	   acid,	   hydrogen	  
peroxide	   and	   saline,	   after	   3	   years	   of	   follow-­‐up,	   a	   significant	   decrease	   of	   PPD	   was	  
observed	  in	  both	  groups,	  without	  intergroup	  differences	  (16);	  with	  a	  bone	  substitute	  
and	  decontamination	  with	  hydrogen	  peroxide	  and	  saline,	  one-­‐year	  results	  showed	  no	  
bleeding	   in	  75%	  of	   implants	   in	  both	  groups,	  and	  similar	  PPD	  reduction,	  CAL	  gain	  or	  
defect	  fill	  (41),	  with	  3-­‐year	  results	  confirming	  the	  previous	  finding	  (40).	  	  
• When	   comparing	  different	   approaches	  of	   reconstructive	   surgery,	   some	   conclusions	  
based	   on	   surrogate	   parameters	   were	   drawn.	   The	   comparison	   of	   a	   graft	   of	   nano-­‐
apatite	   versus	   a	   bovine	   xenograft,	  with	   collagen	  membranes	   and	   decontamination	  
with	  plastic	  curettes	  and	  CHX	  as	  gel	  and	  solution,	  despite	  initially	  similar	  results	  (48),	  
showed	  after	  4	  years	  that	  the	  usage	  of	  xenograft	  and	  collagen	  membrane	  appeared	  
superior	  in	  terms	  of	  PPD	  reduction	  and	  CAL	  gain	  (52).	  
	  
Peri-­‐implantitis	  surgical	  therapy:	  summary	  and	  conclusions	  
Although	   the	   presented	   evidence	   is	   very	   limited	   to	   establish	   solid	   conclusions	   and	  
recommendations,	  some	  suggestions	  can	  be	  made	  based	  on	  the	  available	  evidence.	  
	  
The	  characteristics	  of	  the	  peri-­‐implant	  bone	  defects	  caused	  by	  peri-­‐implantitis	  may	  help	  to	  
select	   the	   most	   suitable	   surgical	   approach.	   A	   classification	   has	   been	   proposed	   for	  
categorizing	   the	   morphology	   of	   the	   peri-­‐implant	   defects	   and	   based	   on	   this	   morphology	  
develop	  a	  decision	  making	  tree	  for	  the	  recommended	  surgical	  intervention	  (49).	  In	  presence	  
of	   circumferential	   bony	   defects	   with	   intact	   bony	   walls	   the	   use	   of	   regenerative	   surgical	  
approaches	   provided	   improved	   outcomes	   when	   compared	   with	   some	   degree	   of	   buccal	  
dehiscence	  morphologies	  (54).	  Therefore,	  regenerative	  surgical	  techniques	  should	  be	  used	  in	  
presence	  of	  circumferential	  and	  intrabony	  defects.	  On	  the	  other	  hand,	  when	  defects	  show	  a	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predominant	  suprabony	  component,	  an	  apical	  repositioned	  flap	  should	  be	  recommended	  in	  
non-­‐aesthetic	  areas.	  Finally,	  even	  though	  there	  is	  no	  evidence	  to	  support	  the	  use	  of	  access	  
flaps,	   they	  may	   be	   suggested	   for	   shallow	   defects	   or	   in	   aesthetic	   areas	   after	   unsuccessful	  
non-­‐surgical	  treatment.	  	  
	  
In	   terms	   of	   surface	   decontamination	   (Figures	   14a-­‐d),	   literature	   is	   not	   clearly	   indicating	  
superiority	  of	  a	  specific	  decontamination	  protocol.	  In	  fact,	  the	  usage	  of	  lasers	  did	  not	  show	  
additional	   advantages	   over	   traditional	   systems	   (8,	   53),	   and	   even	   rinsing	   with	   saline	   has	  
shown	  successful	  outcomes	  (46).	  
	  
There	   is	   no	  evidence	   to	   recommend	   the	  use	  of	   a	   specific	   regenerative	   surgical	   technique,	  
being	  grafting	  with	  autogenous	  or	  xenogeneic	  grafts	  or	  bone	  substitutes,	  although	  it	  seems	  
clear	  that	  the	  use	  of	  barrier	  membranes	  does	  not	  provide	  a	  clear	  added	  value	  (16,	  40,	  41).	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Table	  1.	  Diagnostic	  criteria	  for	  peri-­‐implant	  mucositis.	  
	  
First	  author,	  year	   Mucositis	  definition	  
Heitz-­‐Mayfield	  et	  al.	  (2011)	  (14)	   BOP	  &	  no	  BL	  
Thöne-­‐Mühling	  et	  al.	  (2010)	  (62)	   BOP	  and/or	  GI	  ≥1	  on	  at	  least	  one	  site	  &	  no	  BL	  in	  the	  previous	  2	  y	  
Ramberg	  et	  al.	  (2009)	  (29)	   BOP	  
Porras	  et	  al.	  (2002)	  (28)	   Plaque	  &	  PPD	  ≤	  5mm	  &	  low	  inflammation	  mSBI	  
Felo	  et	  al.	  (1997)	  (10)	   BOP	  &	  mGI	  >1.5	  &	  mPl>1.5;	  PPD	  ≤3mm	  
Ciancio	  et	  al.	  (1995)	  (6)	   BOP	  &	  mGI	  >1.5	  &	  mPI	  >1.7	  
	  
BOP,	  bleeding	  on	  probing;	  BL,	  bone	  loss;	  GI,	  gingival	  index;	  PPD,	  probing	  pocket	  depth;	  mGI,	  modified	  GI;	  mSBI,	  
modified	  sulcular	  bleeding	  index;	  mPI,	  modified	  plaque	  index.	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Table	  2.	  Diagnostic	  criteria	  for	  peri-­‐implantitis.	  
	  
First	  author,	  year	   Peri-­‐implant	  disease	  definition	  
Schar	  et	  al.	  (2012)	  (44)	   PPD:	  4-­‐6mm	  &	  BOP	  at	  >	  1site	  &	  RBL:	  0.5-­‐2mm	  
Renvert	  et	  al.	  (2011)	  	  (33)	   PPD≥5mm	  &	  BOP/SUP	  &	  RBL>3mm	  
Renvert	  et	   al	   (2009)	   (37),	  Persson	  et	  
al.	  (2010)	  (25)	  
PPD≥4mm	  &	  BOP/SUP	  &	  RBL<2.5mm	  
Renvert	  et	  al.	  (2008)	  (31)	  
PPD≥4mm	  &	  BOP/SUP	  &	  BL<1.8mm	  (3	  threads)	  &	  	  
presence	  of	  Pg,Pi,Pn,Tf,Aa,Td	  
Renvert	  et	  al.	  (2004,	  2006)	  	  (30,	  32)	  
PPD≥4mm	  &	  BOP/SUP	  &	  BL<3	  threads	  &	  	  
presence	  of	  Pg,Pi,Pn,Tf,Aa,Td	  
Schwarz	  et	  al.	  (2005,	  2006)	  (47,	  56)	  
Moderate	  (PPD>4mm)	  to	  advanced	  (PPD>7mm)	  BL	  &	  BOP/Sup	  &	  PI<1	  
&	  keratinized	  mucosa	  
Karring	  et	  al.	  (2005)	  (15)	   PPD≥5mm	  &	  BOP	  &	  RBL=1.5mm	  &	  exposed	  implant	  threads	  
Aghazadeh	  et	  al.	  (2012)	  (1)	  
PPD	   >	   5mm	   &	   BOP/SUP	   &	   RBL>	   2mm	   &	   Angular	   peri-­‐implant	   bone	  
defects	  >	  3mm	  	  	  	  
Schwarz	  et	  al.	  (2011)	  (53)	   PPD>6mm	  &	  RBL>3mm	  
Roos-­‐Jansåker	  et	  al.	  (2007)	  (41)	   BOP/SUP	  &	  BL>3	  threads	  
Deppe	  et	  al.	  (2007)	  (8)	   PPD	  >4mm	  or	  BOP,	  vertical	  BL	  
Schwarz	  et	  al.	  (2006,	  2008,	  2009)	  (48,	  
52,	  55)	  
PPD>6mm	  &	  RBL>3mm	  
Romeo	  et	  al.	  (2005,	  2007)	  (38,	  39)	   PPD>4mm	  &	  BOP/SUP	  &	  peri-­‐implant	  radiolucency	  
Khoury	  &	  Buchmann	  (2001)	  (16)	   RBL>50%	  
	  
BOP,	  bleeding	  on	  probing;	  SUP,	  suppuration;	  BL,	  bone	  loss;	  RBL;	  radiographic	  BL;	  PPD,	  probing	  pocket	  depth;	  PI,	  
plaque	  index.	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up	   n	   Intervention	  
Probing	  Pocket	  Depth	   Bleeding	  on	  Probing	  
Baseline	   Final	   Baseline	   Final	  
Schar,	  2012	  (44)	   6	  m	  
20	   TiC	  +	  Gly	  air-­‐abrasive	  +	  Diode	  laser	   4.19	  (0.55)	   3.83	  (0.58)	   4.03	  (1.66)	   1.51	  (1.41)	  
20	   TiC	  +	  Gly	  air-­‐abrasive+	  MIN	   4.39	  (0.77)	   3.90	  (0.78)	   4.41	  (1.47)	   2.10	  (1.55)	  
Sahm,	  2011	  (42)	   6	  m	   15	   Carbon-­‐fibre	  curette	  +	  CHX	   4	  (0.8)	   3.5	  (0.8)	   95.3(9.6)%	   84.3(15.5%)	  
15	   Gly	  air-­‐abrasive	   3.8	  (0.8)	   3.2	  (0.9)	   94.6	  (15.8)%	   51.1(24.7)%	  
Persson,	  2011	  
(24)	   6	  m	  
21	   Air-­‐abrasive	   6.2	  (1.9)	   6.2	  (1.9)	   	   	  
21	   Er:YAG	  laser	   5.9	  (1.7)	   5.9	  (1.7)	   	   	  
Renvert,	  2011	  
(33)	   6	  m	  
21	   Air-­‐abrasive	  	   Change:	  0.8	  (0.5)	   	   No	  BOP:	  25%	  





17	   TiC	   4.0	  (0.8)	   4.0	  (0.8)	   1.7	  (0.6)	   1.2	  (0.7)	  
14	   Ultrasonic	  device	   4.3	  (0.6)	   3.9	  (0.8)	   1.7	  (0.9)	   1.4	  (1)	  
Renvert,	  2008	  
(31)	   12	  m	  
58	  IOI	   Carbon-­‐fibre	  curettes	  +	  CHX	   3.87	  (1.16)	   3.72	  (1.02)	   86.5	  (20)	   48.1	  (21)	  
37	  IOI	   Carbon-­‐fibre	  curettes	  +	  MIN	   3.85	  (1.04)	   3.55	  (0.98)	   89.2	  (17)	   63.5	  (19)	  
Renvert,	  2006	  
(30)	   12	  m	  
14	   Carbon-­‐fibre	  curettes	  +CHX	  	   3.9	  (0.3)	   3.9	  (0.4)	   86	  (14)	   78	  (13)	  
16	   Carbon-­‐fibre	  curettes	  +	  MIN	   3.9	  (0.7)	   3.6	  (0.6)	   88	  (12)	   71	  (22)	  
Renvert,	  2004	  
(32)	   3	  m	  
14	   Carbon-­‐fibre	  curettes	  +CHX	  	   3.9	  (0.3)	   3.9	  (0.3)	   86	  (14)	   78	  (13)	  
16	   Carbon-­‐fibre	  curettes	  +	  MIN	   3.9	  (0.3)	   3.5	  (0.6)	   88	  (12)	   71	  (22)	  
Schwarz,	  2006	  
(47)	   12	  m	  
8	   Plastic	  curettes	  +	  CHX	   Mod:	  4.5	  (0.8)	  Adv:	  6.0	  (1.3)	  
Mod:	  4.3	  (0.5)	  
Adv:	  5.6	  (0.9)	  
	   	  
10	   Er:YAG	  laser	   Mod:	  4.6	  (0.9)	  Adv:	  5.9	  (0.9)	  
Mod:	  4.1	  (0.4)	  
Adv:	  5.5	  (0.6)	  
	   	  
Schwarz,	  2005	  
(56)	   6m	  
9	   Plastic	  curettes	  +CHX	   5.5	  (1.5)	   4.8	  (1.4)	   80	   58	  
10	   Er:YAG	  laser	   5.4	  (1.2)	   4.6	  (1.1)	   83	   31	  
Karring,	  2005	  
(15)	   6	  m	  
11	   Carbon-­‐fibre	  curettes	   6.2	  (1.6)	   6.3	  (2.2)	   72.7	   81.8	  
11	   Ultrasonic	  device	   5.8	  (1.1)	   5.8	  (1.2)	   63.6	   36.4	  
Buchter,	  2004	  (5)	   4.5	  m	  
14	   Plastic	  curettes	   5.68	  (0.28)	   5.4	  (0.34)	   0.63	  (0.1)	   0.5	  (0.1)	  
14	   Plastic	  curettes	  +	  doxycycline	   5.64	  (0.32)	   4.49	  (0.29)	   0.54	  (0.1)	   0.27	  (0.1)	  
IOI:	  Implants;	  Mod:	  moderate;	  Adv:	  advanced;	  TiC:	  Titanium	  curettes;	  Gly:	  Glycine-­‐based;	  CHX,	  chlorhexidine;	  MIN,	  local	  minocycline.	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Table	  4.	  Surgical	  treatment	  of	  peri-­‐implantitis:	  interventions	  and	  main	  outcomes	  of	  selected	  studies.	  
	  
AFS:	  Access	  flap	  surgery;	  IOI:	  Implants;	  B-­‐TCP:	  Beta-­‐tricalcium	  phosphate;	  AuB:	  Autologous	  bone;	  RMb:	  Resorbable	  membrane;	  NRMb:	  Non-­‐
resorbable	  membrane;	  PlasC,	  plastic	  curette;	  CHX,	  chlorhexidine;	  IPla,	  implantoplasty	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up	   n	   Decontamination	   Intervention	  
Probing	  Pocket	  Depth	   Bleeding	  on	  Probing	  
Baseline	   Final	   Baseline	   Final	  
Aghazade,	  2012	  (1)	   12m	   22	   H2O2	  (3%)	  
AFS+	  AuB	   6.0	  (1.3)	   3.8	  (0.2)	   87.5(20.1)%	   48.4(5.4)%	  
23	   AFS	  +	  Bio-­‐Oss	   6.2	  (1.4)	   3.3	  (0.2)	   79.4(28.9)%	   26.7(4.7)%	  
Schwarz,	  2012	  (51)	   24m	   14	   PlasC	  +	  saline	   AFS	  +	  Ipla	  +	  BioOss	  +	  RMb	   5.2	  (1.5)	   3.7	  (1.1)	   100	  (0.0)%	   45.1	  (30.4)%	  
10	   Er:	  YAG	  laser	   4.9	  (1.4)	   3.8	  (1.3)	   96.6	  (10.6)%	   21.6(33.3)%	  
Schwarz,	  2011	  (53)	   6m	   15	   PlasC	  +	  saline	   AFS	  +	  IPla	  +	  BioOss	  +	  RMb	  
5.5	  (1.8)	   3.1	  (0.6)	   100	  (0.0)%	   45.0	  (31.2)%	  
15	   Er:	  YAG	  laser	   5.1	  (1.6)	   3.4	  (0.6)	   93.3	  (18.7)%	   45.5	  (33.0)%	  
Schwarz,	  2009	  (52)	   48m	   9	   PlasC	  +	  saline	   AFS	  +	  nanocristal	  HAP	   6.9	  (0.6)	   5.8	  (0.7)	   80%	   48%	  
11	   AFS	  +	  BioOss	  +	  RMb	   7.1	  (0.7)	   4.6	  (0.9)	   79%	   28%	  
Schwarz,	  2008	  (55)	   24m	   9	   PlasC	  +	  saline	   AFS	  +	  nanocristal	  HAP	   6.9	  (0.6)	   5.4	  (0.7)	   80%	   44%	  
11	   AFS+BioOss+RMb	   7.1	  (0.8)	   4.7	  (0.7)	   78%	   34%	  
Schwarz,	  2006	  (48)	   6m	  
11	  
PlasC	  +	  saline	  
AFS	  +	  nanocristal	  HAP	   7.0	  (0.6)	   4.9	  (0.6)	   82%	   30%	  
11	   AFS+BioOss+RMb	   7.1	  (0.8)	   4.5	  (0.7)	   78%	   28%	  
Romeo,	  2005	  (38)	   24m	  
7	   Metronidazol	  +	  
tetracycline	  +	  saline	  
Resective	  surgery	  +	  IPla	   5.79	  (1.69)	   3.58	  (1.06)	   2.83	  (0.47)	   0.61	  0.67)	  
10	   Resective	  surgery	   6.52	  (1.62)	   5.5	  (1.47)	   2.86	  (0.35)	   2.33	  (0.74)	  





0.2%	  CHX	  +	  citric	  acid	  
H2O2+	  0.9%	  saline	  
AFS	  +	  AuB	   6.40	  (0.90)	   2.90	  (0.60)	   NR	   NR	  
11	   AFS+	  AuB	  +	  NRMb	   6.70	  (1.10)	   2.80	  (1.30)	   NR	   NR	  
7	   AFS	  +	  AuB	  +	  RMb	   6.40	  (0.90)	   5.10	  (1.20)	   NR	   NR	  
Ross-­‐Jansaker,	  
2007	  (41)	   12m	  
29	  IOI	  
H2O2	  (3%)	  +	  saline	  
AFS	  +	  Algipore	  +	  RMb	   5.44	  (1.78)	   2.86	  (2.00)	   79.3%	   21.6%	  
36	  IOI	   AFS	  +	  Algipore	   5.64	  (1.84)	   3.44	  (1.58)	   92.9%	   25%	  
Deppe,	  2007	  (8)	   20-­‐236m	  
17	  IOI	   CO2	  Laser	  
Resective	  surgery	  	   5.70	  (1.40)	   3.40	  (1.50)	   2.80	  (1.20)	   1.80	  (1.10)	  
13	  IOI	   B-­‐TCP	  +	  RMb	  	   5.70	  (1.40)	   2.50	  (1.40)	   3.30	  (0.60)	   1.90	  (1.00)	  
16	  IOI	   Air	  abrasive	   Resective	  surgery	   6.20	  (1.80)	   4.30	  (1.20)	   2.70	  (0.90)	   1.10	  (1.20)	  
11	  IOI	   B-­‐TCP	  +	  RMb	  	   5.10	  (1.70)	   2.50	  (1.10)	   2.30	  (1.40)	   2.10	  (1.40)	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